515 related articles for article (PubMed ID: 22013886)
1. Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study.
Del Prato S; Nicolucci A; Lovagnini-Scher AC; Turco S; Leotta S; Vespasiani G;
Diabetes Technol Ther; 2012 Feb; 14(2):175-82. PubMed ID: 22013886
[TBL] [Abstract][Full Text] [Related]
2. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
3. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
Owens DR; Luzio SD; Sert-Langeron C; Riddle MC
Diabetes Obes Metab; 2011 Nov; 13(11):1020-7. PubMed ID: 21679291
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
5. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
Blonde L; Merilainen M; Karwe V; Raskin P;
Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
[TBL] [Abstract][Full Text] [Related]
6. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
7. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
8. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
[TBL] [Abstract][Full Text] [Related]
9. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
Hanefeld M; Koehler C; Hoffmann C; Wilhelm K; Kamke W; Gerstein H
Diabet Med; 2010 Feb; 27(2):175-80. PubMed ID: 20546261
[TBL] [Abstract][Full Text] [Related]
10. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
Karl D; Zhou R; Vlajnic A; Riddle M
Diabet Med; 2012 Jul; 29(7):933-6. PubMed ID: 22413808
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
12. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
[TBL] [Abstract][Full Text] [Related]
13. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
14. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
[TBL] [Abstract][Full Text] [Related]
15. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
Riddle MC; Rosenstock J; Gerich J;
Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
[TBL] [Abstract][Full Text] [Related]
16. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial.
Harris SB; Yale JF; Berard L; Stewart J; Abbaszadeh B; Webster-Bogaert S; Gerstein HC
Diabetes Care; 2014; 37(3):604-10. PubMed ID: 24170757
[TBL] [Abstract][Full Text] [Related]
17. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
18. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
19. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).
Ratner R; Wynne A; Nakhle S; Brusco O; Vlajnic A; Rendell M
Diabetes Obes Metab; 2011 Dec; 13(12):1142-8. PubMed ID: 21812890
[TBL] [Abstract][Full Text] [Related]
20. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]